Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Pharma
After Alfasigma licensing deal, Lynavoy picks up FDA nod
Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary cholangitis.
Zoey Becker
Mar 19, 2026 10:55am
Fierce Biotech
BioVie plans $20M IPO for spinout developing liver disease drug
Mar 17, 2026 5:18am
Esperion pays $75M for Corstasis and FDA-approved nasal spray
Mar 3, 2026 8:40am
Bausch tumbles as new version of Xifaxan fails ph. 3 trials
Jan 23, 2026 10:21am
FDA approves Corstasis' nasal spray as treatment for edema
Sep 15, 2025 3:33pm
Gilead fashions new primary biliary cholangitis campaign
Sep 10, 2025 7:00am
